Marinus Operating Income vs Reconciled Depreciation Analysis

MRNS Stock

USD 0.33 0.01 3.13%

Marinus Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Marinus Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Marinus Pharmaceuticals is a good investment. Please check the relationship between Marinus Pharmaceuticals Operating Income and its Reconciled Depreciation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marinus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.

Operating Income vs Reconciled Depreciation

Operating Income vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Marinus Pharmaceuticals Operating Income account and Reconciled Depreciation. At this time, the significance of the direction appears to have pay attention.

The correlation between Marinus Pharmaceuticals' Operating Income and Reconciled Depreciation is -0.94. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Marinus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Marinus Pharmaceuticals' Operating Income and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Marinus Pharmaceuticals are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Operating Income i.e., Marinus Pharmaceuticals' Operating Income and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

-0.94

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Marinus Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Marinus Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Reconciled Depreciation

Most indicators from Marinus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Marinus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marinus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.At this time, Marinus Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 602.7 M in 2024, whereas Tax Provision is likely to drop slightly above 94 K in 2024.

Marinus Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment
Total Assets		0.62	0.74	0.83	0.69	0.81	0.55	-0.77	-0.82	0.82	0.99	0.58	0.8	0.4	1.0	0.67	0.78	0.74	0.88	0.74	0.83	-0.59	1.0	0.08	0.67	0.8
Short Long Term Debt Total	0.62		0.91	0.88	-0.08	0.89	0.4	-0.02	-0.88	0.57	0.55	0.25	0.27	0.03	0.61	0.32	0.92	0.9	0.8	0.98	0.9	-0.3	0.63	0.76	0.32	0.89
Other Current Liab	0.74	0.91		0.94	0.15	0.91	0.47	-0.25	-0.96	0.66	0.7	0.38	0.53	0.42	0.73	0.46	0.97	0.96	0.91	0.94	0.94	-0.4	0.74	0.53	0.46	0.91
Total Current Liabilities	0.83	0.88	0.94		0.22	0.88	0.4	-0.39	-0.9	0.73	0.8	0.44	0.68	0.33	0.82	0.42	0.91	0.87	0.86	0.95	0.94	-0.38	0.83	0.4	0.42	0.88
Total Stockholder Equity	0.69	-0.08	0.15	0.22		0.3	0.45	-0.95	-0.3	0.51	0.74	0.52	0.68	0.44	0.69	0.62	0.23	0.21	0.48	0.07	0.28	-0.57	0.67	-0.48	0.62	0.29
Property Plant And Equipment Net	0.81	0.89	0.91	0.88	0.3		0.56	-0.34	-0.97	0.74	0.75	0.47	0.47	0.17	0.79	0.67	0.96	0.92	0.95	0.92	0.99	-0.53	0.8	0.5	0.67	1.0
Current Deferred Revenue	0.55	0.4	0.47	0.4	0.45	0.56		-0.37	-0.56	0.65	0.51	0.38	0.27	0.18	0.53	0.61	0.5	0.56	0.65	0.42	0.53	-0.78	0.54	0.28	0.62	0.56
Net Debt	-0.77	-0.02	-0.25	-0.39	-0.95	-0.34	-0.37		0.35	-0.57	-0.83	-0.49	-0.84	-0.5	-0.78	-0.55	-0.29	-0.26	-0.5	-0.19	-0.36	0.48	-0.76	0.47	-0.55	-0.33
Retained Earnings	-0.82	-0.88	-0.96	-0.9	-0.3	-0.97	-0.56	0.35		-0.75	-0.77	-0.44	-0.51	-0.35	-0.81	-0.62	-0.99	-0.97	-0.97	-0.92	-0.98	0.52	-0.82	-0.5	-0.62	-0.97
Accounts Payable	0.82	0.57	0.66	0.73	0.51	0.74	0.65	-0.57	-0.75		0.8	0.35	0.59	0.27	0.83	0.71	0.68	0.65	0.8	0.66	0.75	-0.74	0.84	0.1	0.71	0.74
Cash	0.99	0.55	0.7	0.8	0.74	0.75	0.51	-0.83	-0.77	0.8		0.54	0.85	0.43	0.99	0.63	0.73	0.69	0.84	0.69	0.78	-0.56	0.99	0.01	0.63	0.75
Non Current Assets Total	0.58	0.25	0.38	0.44	0.52	0.47	0.38	-0.49	-0.44	0.35	0.54		0.58	0.34	0.52	0.44	0.4	0.37	0.52	0.35	0.49	-0.46	0.5	-0.2	0.44	0.47
Non Currrent Assets Other	0.8	0.27	0.53	0.68	0.68	0.47	0.27	-0.84	-0.51	0.59	0.85	0.58		0.67	0.81	0.37	0.48	0.43	0.58	0.45	0.55	-0.34	0.78	-0.33	0.37	0.46
Other Assets	0.4	0.03	0.42	0.33	0.44	0.17	0.18	-0.5	-0.35	0.27	0.43	0.34	0.67		0.4	0.14	0.34	0.36	0.39	0.13	0.24	-0.23	0.38	-0.31	0.14	0.17
Cash And Short Term Investments	1.0	0.61	0.73	0.82	0.69	0.79	0.53	-0.78	-0.81	0.83	0.99	0.52	0.81	0.4		0.65	0.77	0.73	0.86	0.73	0.81	-0.57	1.0	0.08	0.65	0.79
Common Stock Total Equity	0.67	0.32	0.46	0.42	0.62	0.67	0.61	-0.55	-0.62	0.71	0.63	0.44	0.37	0.14	0.65		0.52	0.5	0.69	0.39	0.61	-0.69	0.66	-0.03	1.0	0.66
Common Stock Shares Outstanding	0.78	0.92	0.97	0.91	0.23	0.96	0.5	-0.29	-0.99	0.68	0.73	0.4	0.48	0.34	0.77	0.52		0.98	0.95	0.94	0.97	-0.45	0.78	0.55	0.52	0.96
Other Current Assets	0.74	0.9	0.96	0.87	0.21	0.92	0.56	-0.26	-0.97	0.65	0.69	0.37	0.43	0.36	0.73	0.5	0.98		0.93	0.91	0.93	-0.42	0.75	0.59	0.5	0.92
Other Stockholder Equity	0.88	0.8	0.91	0.86	0.48	0.95	0.65	-0.5	-0.97	0.8	0.84	0.52	0.58	0.39	0.86	0.69	0.95	0.93		0.85	0.95	-0.66	0.87	0.37	0.7	0.95
Total Liab	0.74	0.98	0.94	0.95	0.07	0.92	0.42	-0.19	-0.92	0.66	0.69	0.35	0.45	0.13	0.73	0.39	0.94	0.91	0.85		0.95	-0.36	0.74	0.63	0.39	0.92
Property Plant And Equipment Gross	0.83	0.9	0.94	0.94	0.28	0.99	0.53	-0.36	-0.98	0.75	0.78	0.49	0.55	0.24	0.81	0.61	0.97	0.93	0.95	0.95		-0.5	0.83	0.48	0.62	0.99
Preferred Stock Total Equity	-0.59	-0.3	-0.4	-0.38	-0.57	-0.53	-0.78	0.48	0.52	-0.74	-0.56	-0.46	-0.34	-0.23	-0.57	-0.69	-0.45	-0.42	-0.66	-0.36	-0.5		-0.57	-0.03	-0.69	-0.53
Total Current Assets	1.0	0.63	0.74	0.83	0.67	0.8	0.54	-0.76	-0.82	0.84	0.99	0.5	0.78	0.38	1.0	0.66	0.78	0.75	0.87	0.74	0.83	-0.57		0.11	0.66	0.8
Short Term Debt	0.08	0.76	0.53	0.4	-0.48	0.5	0.28	0.47	-0.5	0.1	0.01	-0.2	-0.33	-0.31	0.08	-0.03	0.55	0.59	0.37	0.63	0.48	-0.03	0.11		-0.03	0.51
Common Stock	0.67	0.32	0.46	0.42	0.62	0.67	0.62	-0.55	-0.62	0.71	0.63	0.44	0.37	0.14	0.65	1.0	0.52	0.5	0.7	0.39	0.62	-0.69	0.66	-0.03		0.67
Property Plant Equipment	0.8	0.89	0.91	0.88	0.29	1.0	0.56	-0.33	-0.97	0.74	0.75	0.47	0.46	0.17	0.79	0.66	0.96	0.92	0.95	0.92	0.99	-0.53	0.8	0.51	0.67

Click cells to compare fundamentals

Marinus Pharmaceuticals Account Relationship Matchups

Marinus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	98.8M	150.5M	136.8M	259.5M	170.9M	102.1M
Other Current Liab	4.8M	8.0M	21.2M	16.5M	22.1M	23.2M
Total Current Liabilities	8.0M	10.7M	40.6M	54.9M	40.6M	42.7M
Total Stockholder Equity	87.8M	137.2M	53.5M	116M	16.8M	15.9M
Property Plant And Equipment Net	2.3M	1.9M	2.5M	4.2M	4.8M	5.1M
Net Debt	(90.5M)	(138.0M)	(82.1M)	(167.9M)	(10.2M)	(10.7M)
Retained Earnings	(235.6M)	(311.9M)	(410.7M)	(430.5M)	(571.9M)	(543.3M)
Accounts Payable	2.8M	2.2M	3.1M	4.5M	4.0M	2.4M
Cash	90.9M	138.5M	122.9M	240.6M	120.6M	88.1M
Non Current Assets Total	4.7M	10.3M	13.9M	19.0M	5.7M	7.8M
Non Currrent Assets Other	2.4M	6.9M	11.4M	14.7M	819K	778.1K
Cash And Short Term Investments	91.7M	138.5M	122.9M	240.6M	150.3M	92.1M
Common Stock Total Equity	53K	87K	37K	50K	57.5K	35.9K
Common Stock Shares Outstanding	13.6M	27.3M	36.7M	39.1M	53.7M	56.4M
Liabilities And Stockholders Equity	98.8M	150.5M	136.8M	259.5M	170.9M	102.1M
Other Current Assets	2.5M	4.6M	6.1M	5.4M	8.7M	9.2M
Other Stockholder Equity	295.1M	444.6M	459.9M	542.4M	588.7M	618.1M
Total Liab	11.1M	13.3M	83.4M	143.5M	154.1M	161.9M
Property Plant And Equipment Gross	2.3M	1.9M	3.9M	5.7M	5.7M	6.0M
Total Current Assets	94.1M	140.2M	122.9M	240.6M	165.2M	94.3M
Accumulated Other Comprehensive Income	(96K)	(2K)	0.0	(20K)	(23K)	(24.2K)
Common Stock	53K	87K	37K	50K	55K	37.9K
Property Plant Equipment	2.3M	1.9M	2.5M	4.2M	4.9M	5.1M
Net Tangible Assets	87.8M	132.7M	53.5M	112.0M	128.8M	76.0M
Retained Earnings Total Equity	(235.6M)	(311.9M)	(410.7M)	(430.5M)	(387.5M)	(368.1M)
Short Term Investments	19.9M	5.0M	739K	1.5M	29.7M	31.2M
Non Current Liabilities Total	3.0M	2.5M	42.8M	88.6M	113.5M	119.2M
Capital Surpluse	295.1M	444.6M	459.9M	542.4M	623.8M	317.7M
Net Invested Capital	59.6M	132.7M	40.8M	71.0M	89.7M	81.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Marinus Stock Analysis

When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC